Sign inJoin
Company / Finance

Viatris Inc.

VTRS · NASDAQ

Viatris reported 2025 revenue of $14.30 billion and Q1 2026 revenue of $3.52 billion. The thesis depends on durable generic-drug cash flow, portfolio pruning, debt reduction, regulatory execution and proof that recent losses are not masking a weakening franchise.

FollowAdd to WatchlistAsk Question
NASDAQVTRSCoverage BootstrapViatris Inc.
Latest ReportMay 20, 2026Viatris: the generics cash engine has to outrun the impairment overhangView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

Viatris: the generics cash engine has to outrun the impairment overhang

Viatris reported 2025 revenue of $14.30 billion and Q1 2026 revenue of $3.52 billion. The thesis depends on durable generic-drug cash flow, portfolio pruning, debt reduction, regulatory execution and proof that recent losses are not masking a weakening franchise.

May 20, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Viatris Inc.the generics cash engine has to outrun the impairment overhangMay 20, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Viatris: the generics cash engine has to outrun the impairment overhangViatris reported 2025 revenue of $14.30 billion and Q1 2026 revenue of $3.52 billion. The thesis depends on durable generic-drug cash flow, portfolio pruning, debt reduction, regulatory execution and proof that recent losses are not masking a weakening franchise.NASDAQMay 20, 2026Research reportReadSlides